Compliance Rate
Compliance Rate
50.0%
Compliant submissions
1
Incompliant submissions
1
Total trials
2
My Organizations' Clinical Trials
Showing 2525 of 3499 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/06/07
End: 01/01/28
Due: 01/01/29
Phase: N/A
Priority: Normal
Start: 08/09/07
End: 09/28/11
Due: 09/28/12
Phase: N/A
Priority: Normal
Start: 11/30/10
End: 08/31/15
Due: 08/31/16
Phase: N/A
Priority: Normal
Start: 04/30/02
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 03/08/01
End: 07/27/15
Due: 07/27/16
Phase: N/A
Priority: Normal
Start: 05/15/12
End: 07/31/24
Due: 07/31/25
Phase: N/A
Priority: Normal
Start: 06/05/20
End: 09/17/20
Due: 09/17/21
Phase: N/A
Priority: Normal
Start: 11/30/10
End: 11/27/12
Due: 11/27/13
Phase: N/A
Priority: Normal
Start: 10/31/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 02/23/23
End: 07/01/26
Due: 07/01/27
Phase: N/A
Priority: Normal
Start: 12/31/04
End: 09/30/10
Due: 09/30/11
Phase: N/A
Priority: Normal
Start: 12/01/07
End: 01/31/26
Due: 01/31/27
Phase: N/A
Priority: Normal
Start: 09/30/08
End: 12/31/12
Due: 12/31/13
Phase: N/A
Priority: Normal
Start: 06/30/03
End: 06/27/08
Due: 06/27/09
Phase: N/A
Priority: Normal
Start: 04/30/05
End: 08/31/11
Due: 08/31/12
Phase: N/A
Priority: Normal
Start: 09/29/08
End: 10/23/14
Due: 10/23/15
Phase: N/A
Priority: Normal
Start: 11/30/04
End: -
Due: -
Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Phase: N/A
Priority: Normal
Start: 10/31/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 04/30/00
End: 02/28/09
Due: 02/28/10
Phase: N/A
Priority: Normal
Start: 11/30/03
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/31/07
End: 06/30/13
Due: 06/30/14
Phase: N/A
Priority: Normal
Start: 01/31/09
End: 10/31/13
Due: 10/31/14
Phase: N/A
Priority: Normal
Start: 09/24/15
End: 08/01/50
Due: 08/01/51
Phase: N/A
Priority: Normal
Start: 01/31/04
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 05/31/04
End: -
Due: -